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Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine
skin tumour, mostly affecting elderly individuals. The majority of
primary MCCs occur on sun-exposed areas of the skin, implicating
UV exposure in its aetiology. The tumour is thought to originate
from Merkel cells, which have properties of both epithelial and
neuroendocrine cells. They are located in the basal epidermis and
are likely to play a role in signal transduction as receptors for
mechanical stimuli in all animals (Ratner et al, 1993).
Until now, little was known about the genetic basis of MCC.
Only 13 cytogenetic studies have been reported in the literature
(Mitelman et al, 1998). No consistent translocations have been
observed but structural abnormalities involving the short arm of
chromosome 1 have been noted in 40% of all examined cases.
Chromosome region 1p36, which is frequently deleted in a variety
of neoplasms including neuroendocrine tumours such as neuro-
blastoma, is often affected in MCC tumours with 1p rearrange-
ments (Van Gele et al, 1998). Several candidate tumour suppressor
genes have been mapped to 1p36 but as yet no direct involvement
of these genes in tumours with 1p36 loss could be found (Schwab
et al, 1996).
The p73 gene, located on 1p36.33, has also been considered 
as a candidate tumour suppressor gene. p73 shows significant
sequence similarity to the transactivation, DNA-binding and
oligomerization domain of TP53 (Kaghad et al, 1997). Jost et al
(1997) showed that overexpression of p73 can activate the tran-
scription of TP53-responsive genes like p21wafl/cipl and inhibit cell
growth in the same way as TP53 by inducing apoptosis. Mutation
analyses for the p73 gene have been performed in lung carcinoma,
oligodendrogliomas, prostatic carcinoma, neuroblastomas,
colorectal carcinoma, oesophageal carcinoma and hepatocellular
carcinoma (Kovalev et al, 1998; Mai et al, 1998a, 1998b; Nimura
et al, 1998; Nomoto et al, 1998; Sunahara et al, 1998; Takahashi et
al, 1998; Ichimiya et al, 1999; Mihara et al, 1999). Except for two
mutations in primary neuroblastomas resulting in amino acid
substitutions in the C-terminal region of p73 (Ichimiya et al,
1999), no other mutations have been reported.
We decided to perform mutation analysis of the p73 gene in
order to investigate the possible involvement of p73 in MCC onco-
genesis. Five MCC cell lines and ten MCC tumours with known
1p status were examined for mutations in the p73 gene by direct
sequence analysis. In view of the possible complementary func-
tions of p73 and TP53, the status of TP53 was also investigated.
MATERIALS AND METHODS
Samples
Tumour samples were collected at the University Hospitals of
Ghent and Leuven, Belgium and the University of Nebraska
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Medical Center, Ohama, NE, USA. One part of the sample was
snap-frozen in liquid nitrogen and another part was stored at
–80°C until analysis. MCC tumour cell line UISO was kindly
provided by Dr SG Ronan and Prof Dr TK Das Gupta (Illinois,
USA). Cell line MKL-1 was given by Prof Dr ST Rosen (Illinois,
USA). Cell lines MCC13, MCC14/2 and MCC26 were a gift from
Dr JH Leonard (Queensland, Australia). All cell lines were grown
in RPMI-1640 medium (Gibco-BRL, 52400-025). DNA of the
tumour samples and cell lines was prepared by standard proteinase
K digestion, phenol–chloroform extraction, and ethanol precipita-
tion protocols. Constitutional DNA of the patients was isolated by
using the Qiagen blood and cell culture Midi Kit (Westburg,
13343). RNA extraction from the tumour samples and cell lines
was done with RNeasy Midi Kits (Westburg, 75144).
Fluorescence in situ hybridization
In order to determine the copy number of chromosome 1 and pres-
ence or absence of 1p deletions, fluorescence in situ hybridization
(FISH) was performed on metaphases or interphase nuclei
according to Van Roy et al (1994). DNA probes used were
pUC1.77 (D1Z1) for the heterochromatic region of chromosome 
1 (1q12) and p1–79 (D1Z2) for the subtelomeric region of
chromosome 1 (1p36.33).
Reverse transcriptase polymerase chain reaction and
sequencing analysis
cDNA synthesis was performed using 5 mg of total RNA incubated
in a 20 ml volume reaction containing 50 mM Tris–HCl (pH 8.3),
10 mM dithiothreitol (DTT), 10 mM potassium chloride (KCl), 0.5
mM dNTP, 20 U RNAsin (Promega), 150 U Super-script II
Reverse Transcriptase (Gibco-BRL) and 50 ng ml–1
oligo-d(T) primer for 1 h at 37°C. The primer pairs sense: 
5¢-AGGGGACGCAGCGAAACC; antisense: 5¢-GGCAGCTTG-
GGTCTCTGG; and sense: 5¢-GGTGACACGCTTCCCTG; anti-
sense: 5¢-GGTGGGAGGCTGTCAGTG were used to amplify the
entire coding region of p73 and TP53 respectively by reverse tran-
scription polymerase chain reaction (RT-PCR). Long range PCR
was performed using the Expand™ Long Template PCR system
(Boehringer Mannheim). PCR reactions were performed in a 50 ml
reaction volume containing 2 ml of reverse transcriptase products,
500 mM dNTP, 300 nM primers, 10% dimethylsulphoxide, 5 ml of
buffer 1 and 3.5 units of Taq and Pwo enzyme mix. The PCR
amplification consisted of 35 cycles of 95°C for 0.5 min, 58°C for
1 min, 68°C for 2.5 min after starting with a denaturing step at
95°C for 1 min and ending at 68°C for 10 min. The PCR products
were purified by spin dialysis sequentially on S400 and P10 resins.
Subsequently, the PCR products were directly completely
sequenced on an ABI PRISM™ 377 sequencer (Perkin-Elmer)
using specific nested sequencing primers and the Big Dye
Terminator Sequencing Kit. Cases 6, 7, 8, 9 and 10 (see Table 1)
were sequenced on an ALF™ Express automated DNA sequencer
(Pharmacia) using a Thermo Sequenase fluorescent labelled
primer cycle sequencing kit with 7-deaza-dGTP (Amersham, RPN
2438). To confirm the p73 nucleotide change found in case 4 
the following primer pair sense: 5¢-CCAGTTCAATCTGCTGA-
GCAG-3¢ and antisense: 5¢-CCACTTTGAGGTCACTTTCC-3¢,
located in exon 4, were used to amplify genomic tumour DNA and
constitutional DNA of the patient. PCR conditions were the same
as those described above. The PCR products were sequenced using
the same primers as those to amplify genomic DNA.
Table 1 Summary of mutation analysis of p73 and TP53 in Merkel cell carcinoma
Cell lines 1pDa Expressed p73 Transcript AA change TP53 Transcript AA change
allele(s)b sequence sequence
UISO Noc G/C wt – wt –
MKL-1 No G/C wt – wt –
MCC13 No G/C;A/T wt – mut 857C>T;858C>T S241F
mut 967C>T P278S
MCC14/2 No G/C wt – mut950T>A V272E
MCC26 No G/C wt – N/Ad
MCC samples
Case 1 No G/C;A/T 1118C>T;1157T>Ce No wt –
1781G>A;1940G>A No
Case 2 Yes A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A No
Case 3 No G/C;A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A
Case 4 No G/C;A/T mut 439C>T S110L mut550A>T K139X
Case 5 Yes G/C;A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A
Case 6 NT G/C wt – wt –
Case 7 No G/C;A/T wt – wt –
Case 8 No G/C;A/T wt – wt –
Case 9 No G/C;A/T wt – wt –
Case 10 No G/C;A/T wt – wt –
a 1pD, deletion in the short arm of chromosome 1 determined by fluorescence in situ hybridization with the telomeric D1Z2 probe
performed on chromosome metaphases or interphase nuclei. NT: not tested. b Refers to the polymorphism of G/C and A/T alleles in exon
2, as determined by RT-PCR on mRNA and subsequent sequencing of products. c UISO carries an insertion on 1p36.2 of unknown origin
(Van Gele et al, 1998). d NA, not available due to lack of TP53 mRNA expression, as determined by RT-PCR. eRefers to the tightly linked
polymorphisms located in exon 9 and exon 14, as determined by RT-PCR on mRNA and subsequent sequencing of products.RESULTS
Mutation analysis of p73 and TP53 in MCCs
cDNA of five MCC cell lines and ten MCC tumours was amplified
by RT-PCR and, consequently, cycle-sequenced using specific
nested PCR primers for the detection of mutations in p73. In addi-
tion, allelic expression for p73 was determined based upon the
known linked polymorphisms in exon 2. The sequencing results
and allelic expression data are summarized in Table 1. A C to T
mutation at codon 110 was found in one out of ten MCC tumours
for  p73, resulting in a serine to leucine substitution. This
nucleotide exchange was also present in the genomic DNA of the
tumour but not in the constitutional DNA (Figure 1). No mutations
were found in the cell lines. Silent nucleotide substitutions at
codon 336 (GCC to GCT) and codon 349 (CAT to CAC) located in
exon 9 and at codon 557 (GCG to GCA) and at codon 610 (GCG to
GCA) located in exon 14 were found in four (40%) of the ten
examined tumours. These polymorphisms were also found in the
constitutional patient DNA.
The same panel of MCC cell lines and MCC tumours was also
examined for mutations in the TP53 gene. Four TP53 mutations
were found in two out of five MCC cell lines and one non-sense
mutation was observed in one MCC tumour (see Table 1).
DISCUSSION
Thus far, mutation analyses for p73 have been performed in
several types of carcinomas, oligodendrogliomas and neuroblas-
tomas (Kovalev et al, 1998; Mai et al, 1998a, Nimura et al, 1998;
Nomoto et al, 1998; Sunahara et al, 1998; Takahashi et al, 1998;
Ichimiya et al 1999; Mihara et al, 1999). No mutations were found
except for one somatic and one germline mutation in a series of
140 neuroblastomas (Ichimiya et al, 1999). Like MCC, neuro-
blastoma is a tumour of neuroendocrine origin frequently carrying
distal 1p deletions. The two mutations found in neuroblastoma
(P405R and P425L) were located within the COOH-terminal
region of p73 (Ichimiya et al, 1999). Recently, Takada et al (1999)
showed that the COOH terminus of p73 had a transactivation func-
tion whose activity was significantly reduced by the mis-sense
mutations detected in the neuroblastoma tumours.
In the present study, one mis-sense mutation of p73 in one out of
ten MCC tumours was found: a heterozygous C to T transition at
nucleotide 439, resulting in a serine to leucine substitution at
codon 110 within exon 4. In comparison to the mutations observed
in neuroblastoma, this mutation was located in the NH2-terminal
region (residues 1–112) of p73. The transcriptional transactivation
function of the NH2-terminal region of p73 was shown to have an
activity as strong as that of TP53 (Takada et al, 1999). Further
analysis may show that the observed mis-sense mutation in MCC
leads to a reduction or complete loss of the transactivation function
of the NH2-terminal region of p73. The MCC tumour carrying the
mutated p73 allele still expresses the remaining wild-type allele.
Similar to TP53, this mis-sense mutation might exert a dominant
negative effect by an increased stability of the mutant protein
compared to that of wild-type protein. Further studies are needed
to verify this hypothesis.
The finding of p73 mutations in neuroblastoma and MCC may
also stimulate mutation analyses in other tumour types. Although
the low frequency of mutations in both tumours seems to exclude a
direct role for p73 in tumorigenesis, other mechanisms than muta-
tions in p73 may lead to tissue-specific up- or down-regulation of
the gene. In this respect, the available data on allelic expression of
p73 are conflicting. Nomoto et al (1998) found biallelic expression
of p73 in normal lung tissue and distinct patterns of allelic expres-
sion in different normal tissues. In contrast, Mai et al (1998b)
reported monoallelic expression in normal lung tissue and
increased and biallelic expression in lung tumour samples.
Ichimiya et al (1999) found low p73 expression in neuroblastoma,
while p73 transcripts were easily detectable in breast carcinoma
and colorectal carcinoma under the same conditions. Although we
performed no quantification of the p73 mRNA, we observed 
biallelic expression in one MCC cell line and eight MCC primary
tumours. Clearly, further studies on p73 expression in normal and
cancerous tissues is warranted.
As yet, only one study investigated the possible role of TP53 in
MCC (Schmid et al, 1997). Using immunohistochemical staining,
TP53 expression was studied in 25 Merkel cell carcinomas. Only
five tumours showed 5–10% TP53-immunoreactive tumour
nuclei. Single-strand conformation polymorphism (SSCP) analysis
Mutation analysis of p73 and TP53 in Merkel cell carcinoma 825
British Journal of Cancer (2000) 82(4), 823–826 © 2000 Cancer Research Campaign
Figure 1 p73 sequencing profiles of genomic tumour DNA (case 4) showing the heterozygous mutation at codon 110 (TCG®TTG) (A) and of the
constitutional DNA (B)
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for exons 4–8 did not reveal mutations in these five tumours which
lead the authors to conclude that TP53 alterations play only a
minor part in the genesis of MCC. However, using this approach it
could not be ruled out that the presence of mutations in the other
exons of TP53 were missed. Also, mis-sense and non-sense muta-
tions not leading to accumulation of the gene product would be
overlooked in those cases not investigated by SSCP analysis. We
also investigated TP53 for the presence of mutations by
sequencing of the entire coding region of the TP53 gene. TP53
mutations were found in two out of five MCC cell lines and in one
out of ten tumours. In cell line MCC13, three mutations were
found at dipyrimidine sites, namely a double base pair C to T tran-
sition at nucleotides 857, 858 and a single base pair C to T transi-
tion at nucleotide 967 both leading to amino acid substitutions at
codon 241 and codon 278 respectively (Table 1). These type of
mutations are characteristically induced by absorption of UV irra-
diation by the DNA (Brash et al, 1991). The mutation found in
MCC14/2 is a hemizygous T to A transversion at nucleotide 950
since no wild-type sequence was present. This point mutation is
translated into an amino acid substitution from valine to glutamic
acid at codon 272. The amino acid changes at codon 241, 272 and
278 reside in mutational hotspots of the sequence-specific DNA-
binding domain of the TP53 protein. Alterations in these residues
of the TP53 protein will typically result in defective contacts with
the DNA and finally lead to the loss of the ability of TP53 to act as
a transcription factor. For the particular amino acid substitution at
residue 241, Cho et al (1994) could show that DNA contact was
not possible as the defective TP53 protein was unable to make
contact with the phosphate backbone in the major groove of the
DNA. The non-sense mutation at nucleotide 550 in the MCC
tumour (case 4) predicted the generation of a truncated TP53
protein. Accumulation of truncated TP53 variants can result in a
dominant negative effect and loss of normal TP53 function.
In conclusion, we describe the finding of a sporadic p73 NH2-
terminal located mis-sense mutation in MCC together with the
observation of two previously reported loss of function mutations
within the COOH-terminal transactivation region of p73 in
neuroblastoma. These mutations provide circumstantial evidence
for a role of p73 in these malignancies of neuroectodermal origin.
At present, the exact physiological function of p73 in tumour
development is unclear. In view of these findings, we propose
further investigations of p73 in normal development and tumori-
genesis. Further insights in its role in apoptosis (Jost et al, 1997)
and possibly other mechanisms such as cell cycle control and cell
differentation may provide additional clues for possible contribu-
tion of p73 in tumorigenesis. This report also shows for the first
time the occurrence of inactivating TP53 mutations in 19% of the
investigated MCCs. The C to T mutations in cell line MCC13 are
known to be caused by UVB irradiation and thus provide further
evidence for sun-exposure in some Merkel cell carcinomas.
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